Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$392.81 - $485.53 $25,925 - $32,044
-66 Reduced 7.27%
842 $395 Million
Q1 2024

Apr 26, 2024

SELL
$407.69 - $446.08 $710,195 - $777,071
-1,742 Reduced 65.74%
908 $363 Million
Q4 2023

Feb 09, 2024

BUY
$343.0 - $410.68 $908,950 - $1.09 Million
2,650 New
2,650 $1.15 Billion

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Bay Bridge Capital Group, LLC Portfolio

Follow Bay Bridge Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bay Bridge Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bay Bridge Capital Group, LLC with notifications on news.